Live Breaking News & Updates on Anti Tnf

Stay updated with breaking news from Anti tnf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Infliximab and Biosimilar Yield Similar Results in IBD

New data supported the safety and efficacy of nonmedical switching from infliximab to a biosimilar, according to researchers. ....

United Kingdom , British Columbia , Thomas Tam Hoang , Laura Targownik , University Of Toronto Temerty Faculty Medicine , Centre Of British Columbia , Journal Of The Canadian Association Gastroenterology , Health Canada , University Of British Columbia Faculty Medicine , British Columbia Faculty , Medscape Medical , Canadian Association , Medscape Medical News , Mount Sinai Hospital , Temerty Faculty , Inflammatory Bowel Disease Ibd , Biologic Therapy , Biosimilar Drugs , Follow On Biologics , Board Certification , Oard Recertification , Crohn 039s Disease , Crohn Disease , Egional Enteritis Crohn S , Ulcerative Colitis , Lcerative Colitis Uc ,

Pediatric CNO Characteristics Can Predict Therapy Needs

Patients with unifocal disease at diagnosis may require shorter nonsteroidal anti-inflammatory drug monotherapy courses than those with multifocal disease. ....

United States , Melissa Oliver , Katherined Nowicki , Rheumatology Research Alliance , Riley Children Health At Indiana University , Childhood Arthritis , Hospital Colorado , Riley Children , Indiana University Health , North America , Pain Management , Nonsteroidal Anti Inflammatory Drugs , Nonsteroidal Anti Inflammatory Drugs , Onsteroidal Anti Inflammatory Agents , Anti Tnf , Nti Tumor Necrosis Factor Anti Tumour , Chronic Osteomyelitis , None Infection , Osteoporosis Osteoporotic ,

Discussing New Phase 2 Findings on Lutikizumab for Hidradenitis Suppurativa with Alexa Kimball, MD, MPH

Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.
....

United States , Alexa Kimball , Harvard Medical School , American Academy Of Dermatology , Annual Meeting , Hidradenitis Suppurativa Clinical Response , Massachusetts General Hospital , Numeric Rating Scale , Global Assessment , Hidradenitis Suppurativa , Anti Tnf , Phase 2 , Late Breaking ,

Risankizumab in CD: Outcomes Remain Stable up to 3 Years

Long-term data show clinical remission and endoscopic response rates are maintained and even improve over time in patients with moderate to severe Crohn's disease, according to a new study. ....

United Kingdom , Region Flamande , Tim Raine , Marc Ferrante , University Hospitals Leuven , Colitis Organization , Cambridge University Hospitals , Medscape Medical , European Crohn , Label Extension , Clinical Disease Activity Index , Crohn Amp 039s Disease , Crohn Disease , Egional Enteritis Crohn S , Endoscopic Imaging , Endoscopic Ultrasound , Endoscopic Ultrasonography , Us Endoscopic Ultrasonography , Ndoscopic Ultrasound Imaging , Biologic Therapy , Inflammatory Bowel Disease Ibd , Anti Tnf , Nti Tumor Necrosis Factor Anti Tumour , Adverse Effects ,

Marla Dubinsky, MD: Using Off-Label Treatments to Address the Unmet Need in Pediatric IBD

Marla Dubinsky, MD, discusses the use of off-label upadacitinib in pediatric IBD patients and the importance of this research due to delays in pediatric drug approvals. ....

Marla Dubinsky , Drug Administration , Mount Sinai Kravis Children , Mount Sinai , Inflammatory Bowel Disease , Ulcerative Colitis , Crohn X27s Disease , Anti Tnf ,